AI Article Synopsis

  • Women with gestational diabetes mellitus are at increased risk for Gestational Diabetes Induced Myopathy (GDiM), leading to muscle atrophy and urinary incontinence.
  • The study developed a natural rubber latex (NRL) based biodevice infused with mesenchymal/stromal stem cells (MSCs) to aid in skeletal muscle regeneration.
  • The NRL showed promising properties such as biocompatibility, low hemolytic activity, and strong antioxidant activity, indicating its potential as a treatment for GDiM-related muscle issues.

Article Abstract

Women with gestational diabetes mellitus show a high risk of developing Gestational Diabetes Induced Myopathy (GDiM). GDiM is characterized by significant pelvic floor skeletal muscle atrophy and urinary incontinence. This study aimed to develop a natural rubber latex (NRL) based biodevice with mesenchymal/stromal stem cells (MSCs) for skeletal muscle regeneration for women with GDiM. NRL showed porosity, roughness, biocompatibility, and bioactivity. MSCs adhesion on the NRL scaffold surface was assessed by scanning electron microscopy (SEM), confocal microscopy, and zymography. The scaffold's physicochemical and biological properties were carried out by Fourier transform infrared spectroscopy (FTIR), swelling and degradation studies, hemolytic activity, and antioxidant activity (AA), using Electronic Paramagnetic Resonance (EPR). MSCs in culture expressed CD90, adhered to plastic, differentiated, and produced fibroblast colonies. A high rate of cell proliferation was seen in MSCs on the NRL scaffold. FTIR analysis confirmed protein structures and polyisoprene in the scaffold. Swelling and degradation showed low water uptake and weight loss. Furthermore, NRL presented a hemolytic rate of 2.90 ± 0.26 % for 24 h, and EPR revealed the scaffold's strong AA. The generated biodevice has potential for muscle regeneration and may be useful as a therapeutic option for skeletal muscle disorders in GDiM or urinary incontinence.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijbiomac.2024.138777DOI Listing

Publication Analysis

Top Keywords

skeletal muscle
16
muscle regeneration
12
natural rubber
8
stem cells
8
gestational diabetes
8
urinary incontinence
8
nrl scaffold
8
swelling degradation
8
muscle
5
nrl
5

Similar Publications

Focal myositis is a rare, localized, benign, self-limiting, and non-suppurative inflammatory lesion of the skeletal muscle that may occasionally occur as a complication of rheumatic diseases. This case report discusses a 58-year-old patient with rheumatoid arthritis, who was diagnosed with focal myositis during standard immunosuppressive therapy. The patient was treated with tofacitinib; to our knowledge, this is the first reported case of focal myositis managed with this medication.

View Article and Find Full Text PDF

Precision medicine using molecular-target drugs in psoriatic arthritis.

Ther Adv Musculoskelet Dis

January 2025

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu 807-8555, Japan.

Psoriatic arthritis (PsA) presents various clinical manifestations, including skin lesions, peripheral arthritis, axial involvement, enthesitis, nail involvement, dactylitis, and uveitis. In addition, it causes a high incidence of lifestyle-related diseases and an increase in cerebrovascular and cardiovascular events. As the pathology of PsA has been clarified, molecular-targeted drugs targeting tumor necrosis factor-α, interleukin (IL)-17A, IL-17A/F, IL-17 receptor, IL-12/23(p40), IL-23p19, Cytotoxic T-lymphocyte Antigen-4 (CTLA-4), Janus kinase, and phosphodiesterase-4 have been developed and are widely used in clinical practice.

View Article and Find Full Text PDF

sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present case report describes a tumor in a 55-year-old man that was originally thought to be a Ewing-like adamantinoma, but was recently found to be an sarcoma following direct sequencing.

View Article and Find Full Text PDF

Cachexia is a multifactorial metabolic syndrome characterized by weight and skeletal muscle loss caused by underlying illnesses such as cancer, heart failure, and renal failure. Inflammation, insulin resistance, increased muscle protein degradation, decreased food intake, and anorexia are the primary pathophysiological drivers of cachexia. Cachexia causes physical deterioration and functional impairment, loss of quality of life, lower response to active treatment, and ultimately morbidity and mortality, while the difficulties in tackling cachexia in its advanced phases and the heterogeneity of the syndrome among patients require an individualized and multidisciplinary approach from an early stage.

View Article and Find Full Text PDF

Introduction: Clinical trials have shown efficacy of semaglutide for weight loss, but further study is needed in less controlled environments including impacts on body composition.

Materials And Methods: This retrospective study included individuals who participated in a weight management programme at a commercial wellness studio receiving once-weekly compounded semaglutide/cyanocobalamin injections from June 2023 to January 2024. Once-weekly semaglutide/cyanocobalamin injected subcutaneously starting at 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!